AACR-Bayer Innovation and Discovery Grantee Designs an MDM2-Targeted PROTAC to Treat Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an aggressive cancer with high rates of p53 inactivation and lower survival rates than other breast cancer types due to increased metastasis and relapse (1). Owing to the frequent inactivation of p53, compounds that inhibit p53 from binding to its negative regulator, MDM2, are ineffective in TNBC. In a recent study published in Cancer Discovery, Dr. Eischen and her colleagues used an MDM2-targeted PROteolysis TArgeting Chimera (PROTAC) to reveal the requirement for MDM2 in p53 inactivated TNBC and identify a new therapeutic target for the disease.
